- |||||||||| quetiapine / Generic mfg.
[VIRTUAL] Identifying and Treating Steroid-Induced Psychosis in MS Patients Using Quetiapine () - Nov 20, 2021 - Abstract #CMSC2021CMSC_686; As a result of the small sample size and case report methodology, more research is needed to determine the efficacy of antipsychotics for managing steroid-induced psychosis in MS patients. Importantly, a greater clinical awareness is needed for early recognition of steroid-induced psychosis to minimize symptoms and improve patient quality of life.
- |||||||||| Decadron (dexamethasone) / Merck (MSD)
Trial completion date, Trial primary completion date: PROUD Study - Preventing Opioid Use Disorders (clinicaltrials.gov) - Nov 18, 2021 P4, N=170, Recruiting, Prospective study is needed to better characterize the differences between these two modalities. Trial completion date: Oct 2021 --> Apr 2022 | Trial primary completion date: Oct 2021 --> Apr 2022
- |||||||||| magrolimab (ONO-7913) / Ono Pharma
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 18, 2021 P2, N=153, Recruiting, Trial completion date: Oct 2021 --> Apr 2022 | Trial primary completion date: Oct 2021 --> Apr 2022 Not yet recruiting --> Recruiting | Trial completion date: Sep 2023 --> May 2024 | Initiation date: Aug 2021 --> Nov 2021 | Trial primary completion date: Sep 2023 --> May 2024
- |||||||||| Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Trial completion date, Trial initiation date, Trial primary completion date: STARR: Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease (clinicaltrials.gov) - Nov 18, 2021 P1, N=10, Not yet recruiting, Not yet recruiting --> Recruiting | Trial completion date: Sep 2023 --> May 2024 | Initiation date: Aug 2021 --> Nov 2021 | Trial primary completion date: Sep 2023 --> May 2024 Trial completion date: Sep 2024 --> Dec 2024 | Initiation date: Sep 2021 --> Dec 2021 | Trial primary completion date: Sep 2023 --> Dec 2023
- |||||||||| colchicine / Generic mfg., fluvoxamine / Generic mfg., budesonide / Generic mfg.
So true! What if Drs would have been encouraged to treat early and share experiences ? We knew about budesonide, Fluvoxamine, steroids, cyproheptadine, vitamin d, colchicine, etc, etc. how many lives would have been saved. Instead they were attacked. (Twitter) - Nov 17, 2021
- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: Therapeutic potential and deleterious effect of glucocorticoids on azoxymethane/dextran sulfate sodium-induced colorectal cancer in mice. (Pubmed Central) - Nov 17, 2021 Dexamethasone (DEX) was then administered at different periods of time to determine its effect on tumorigenesis and tumor progression...In summary, both early and late DEX interventions significantly ameliorate colonic inflammation and inhibit the progression of AOM/DSS-induced colorectal cancer, at least partly due to the inhibition of MAPK/JNK pathway. It is noteworthy that the deleterious effect on the general condition of mouse may limit the duration of GCs treatment.
- |||||||||| hydrocortisone / Generic mfg.
Clinical, Review, Journal: Metabolic resuscitation in pediatric sepsis: a narrative review. (Pubmed Central) - Nov 17, 2021 Administration of hydrocortisone in children with septic shock might fasten shock resolution, and has been shown to dampen the systemic host immune response, augment adrenergic effects, and support the stress response...A single centre retrospective study identified potential for mortality benefit in children with septic shock, and the results from a randomized controlled pilot trial are being awaited. It is imperative for pediatric research on ascorbic acid and HAT in children with sepsis to critically investigate key questions related to pharmacology, dosing, timing, feasibility, safety, effects on short- and long-term outcomes, and generalisability in view of the global burden of sepsis.
- |||||||||| Reasanz (serelaxin) / Novartis, Esbriet (pirfenidone) / Shionogi, Roche
Journal: Adapting the Scar-in-a-Jar to Skin Fibrosis and Screening Traditional and Contemporary Anti-Fibrotic Therapies. (Pubmed Central) - Nov 17, 2021 Among the anti-fibrotic compounds assessed, trichostatin A (inhibitors of histone deacetylases); serelaxin and pirfenidone (pleiotropic inhibitors of fibrotic activation); and soluble TGFβ receptor trap (inhibitor of TGFβ signalling) resulted in the highest decrease of collagen type I deposition (even higher than triamcinolone acetonide, the gold standard in clinical practice). This study further advocates the potential of macromolecular crowding in the development of in vitro pathophysiology models.
- |||||||||| dexamethasone / Generic mfg., ondansetron / Generic mfg., midazolam hydrochloride / Generic mfg.
Clinical, Journal: Effect of Adding Midazolam to Dual Prophylaxis for Preventing Postoperative Nausea and Vomiting. (Pubmed Central) - Nov 17, 2021 In this prospective, randomized, double-blinded trial, 144 patients undergoing gynecological laparoscopic surgery under sevoflurane anesthesia were randomized to receive either normal saline (control group, n = 72) or midazolam 0.05 mg/kg (midazolam group, n = 72) intravenously at pre-induction...The incidence of nausea, severe nausea, retching/vomiting, and administration of rescue antiemetic was comparable between the two groups. The addition of 0.05 mg/kg midazolam at pre-induction to the dual prophylaxis had no additive preventive effect on PONV after gynecologic laparoscopy.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, APVO436 / Medexus
Biomarker, Clinical, Journal, Cytokine release syndrome: Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436. (Pubmed Central) - Nov 17, 2021 P1b Notably, the development of CRS after APVO436 therapy did not appear to be associated with a response. The prolonged stabilization of disease, partial remissions and complete remissions were achieved in both patients who experienced CRS, as well as patients who did not experience CRS after APVO436 infusions.
- |||||||||| Daklinza (daclatasvir) / BMS
Review, Journal: Deep Learning Driven Drug Discovery: Tackling Severe Acute Respiratory Syndrome Coronavirus 2. (Pubmed Central) - Nov 17, 2021 Consequently, deep learning has been successfully used for the identification of a number of potential drugs against SARS-CoV-2, including Atazanavir, Remdesivir, Kaletra, Enalaprilat, Venetoclax, Posaconazole, Daclatasvir, Ombitasvir, Toremifene, Niclosamide, Dexamethasone, Indomethacin, Pralatrexate, Azithromycin, Palmatine, and Sauchinone. This mini-review discusses recent advances and future perspectives of deep learning-based SARS-CoV-2 drug discovery.
- |||||||||| dexamethasone / Generic mfg.
Review, Journal: Vision Loss Secondary to Facial and Periorbital Steroid Injection: A Systematic Review. (Pubmed Central) - Nov 17, 2021 Dexamethasone has the opposite pharmacologic properties and has never been reported in association with vascular occlusion related vision loss. Careful steroid selection, injection techniques, and treatment strategies should be considered to prevent and treat artery occlusion.
- |||||||||| dexamethasone / Generic mfg.
Journal: Suppression of TGF-β1 signaling by Matrigel via FAK signaling in cultured human trabecular meshwork cells. (Pubmed Central) - Nov 17, 2021 Herein, we validated that our culture system on 2D Matrigel expressed putative TM markers and myocilin, of which the latter was upregulated by dexamethasone...These findings indicate that basement membrane matrix with low rigidity plays an active role in maintaining TM phenotype in the presence of TGF-β1 and shed light on its physiological role. Furthermore, abnormal matrices may perpetuate the pathological TM phenotype when the level of TGF-β2 is elevated in glaucoma patients.
- |||||||||| Ninlaro (ixazomib) / Takeda
Trial completion date, Trial primary completion date, Combination therapy: Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Nov 17, 2021 P1/2, N=30, Active, not recruiting, Furthermore, abnormal matrices may perpetuate the pathological TM phenotype when the level of TGF-β2 is elevated in glaucoma patients. Trial completion date: Feb 2022 --> Jun 2022 | Trial primary completion date: Aug 2021 --> Jan 2022
- |||||||||| dexamethasone / Generic mfg.
Journal: Cheerios Effect Inspired Microbubbles as Suspended and Adhered Oral Delivery Systems. (Pubmed Central) - Nov 17, 2021 Based on these, it is demonstrated as a proof of concept that the dexamethasone-loaded hollow microbubbles can be applied to oral administration and remain suspended and adhered to the stomach of murine for more than 1 d, showing good therapeutic effect in treating lupus erythematosus. Thus, it is believed that the microbubbles floating system will find important values in long-term oral administration.
- |||||||||| Darzalex IV (daratumumab) / J&J
Review, Journal: Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma. (Pubmed Central) - Nov 17, 2021 The combination of bortezomib/lenalidomide/dexamethasone (VRd) has emerged as a standard regimen for both transplant-eligible (TE) and transplant-ineligible (TI) patient populations...In the TI patient population, the combination of daratumumab/lenalidomide/dexamethasone is now considered another standard therapy...The optimal management of newly diagnosed patients with high-risk cytogenetics remains to be determined. We discuss the emerging therapies that will likely shape management of newly diagnosed MM in the future.
- |||||||||| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
Journal: Enhanced alveo pulmonary deposition of nebulized ciclesonide for attenuating airways inflammations: a strategy to overcome metered dose inhaler drawbacks. (Pubmed Central) - Nov 17, 2021 Superior anti-inflammatory and antioxidative stress effects characterized by significant decrease (p< .0001) in inflammatory cytokines IL-4 and 13, serum IgE levels, malondialdehyde (MDA), nitric oxide (NO), TNF-α, and activated nuclear factor-κB (NF-κB) activity were obvious with concomitant increase in superoxide dismutase (SOD) activity. Histological examination with inhibition of inflammatory cell infiltration in the respiratory tract was correlated well with observed biochemical improvement.
- |||||||||| dexamethasone / Generic mfg.
Clinical, Journal, Pleural effusion: Multifocal pleural capillary hemangioma: a rare cause of hemorrhagic pleural effusion-case report. (Pubmed Central) - Nov 17, 2021 Histological examination with inhibition of inflammatory cell infiltration in the respiratory tract was correlated well with observed biochemical improvement. To our knowledge, this is the first case of a patient with recurrent hemorrhagic pleural effusion masquerading as malignant pleurisy, but in fact caused by multifocal pleural capillary hemangioma.
- |||||||||| hydrocortisone / Generic mfg.
Journal: Vitamin C for Sepsis and Septic Shock. (Pubmed Central) - Nov 17, 2021 No abstract available Future studies with consistent end points, initiation time with an emphasis on early initiation, and standard vitamin C dosing regimen are needed to determine the overall benefit of vitamin C in sepsis.
- |||||||||| dexamethasone / Generic mfg.
Clinical, Journal: Non-haemorrhagic uterine rupture at 28 weeks of pregnancy following previous caesarean section: a case report. (Pubmed Central) - Nov 17, 2021 The presence of concurrent immune-mediated conditions, and frequent prescribing of analgesics, including opioids, illustrate the burden of GPP in patients requiring acute and inpatient care. There is need to suspect uterine rupture in pregnant women with previous caesarean section scars if they present with abdominal pain and are found to have severe oligohydramnios despite having no history of any vaginal discharge, even when the fetal heart rate is normal and they are haemodynamically stable and without vaginal bleeding and remote from term.
- |||||||||| dexamethasone / Generic mfg., budesonide / Generic mfg.
Journal: Development of Novel Glucocorticoids for Use in Antibody-Drug Conjugates for the Treatment of Inflammatory Diseases. (Pubmed Central) - Nov 17, 2021 Herein, we describe novel classes of GCs that exhibited greater potency than dexamethasone and budesonide, a 100-fold selectivity toward the GR over other nuclear receptors, and no in vitro safety liability in pharmacology assays (hERG, AMES) and that demonstrated a substantial reduction in tumor necrosis factor-α (TNF-α) release in mice challenged with lipopolysaccharide (LPS). The site-specific conjugated GC-ADCs via cathepsin-cleavable linkers were highly stable in plasma and specifically released GCs in antigen-positive cells, suggesting that these novel GCs can serve as ADC payloads to treat autoimmune and inflammatory diseases.
- |||||||||| Imfinzi (durvalumab) / AstraZeneca
Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma. (Pubmed Central) - Nov 17, 2021 Additionally, multiplex immunofluorescence of bone marrow demonstrated that immune populations were different in responders versus nonresponders to durvalumab plus pomalidomide with dexamethasone therapy. Overall, durvalumab effectively blocked soluble PD-L1; however, durvalumab monotherapy was not associated with immunologic changes, which were observed with combination therapy.
|